Chairman of the Advisory Board of Treofan Holdings GmbH
"As chairman of the advisory board of Treofan Holdings, I have had only the best experiences with Dr. Bickel and his team. Dr. Bickel convinced all stakeholders of his strategy. The realignment was successful and allowed a sale of the company at a higher value than expected."
In 2014, Treofan was facing a severe business crisis requiring a holistic transformation. Despite a recent refinancing, the liquidity situation became under significant pressure once more. At the same time, Treofan was burdened by an inefficient organizational structure that was not fit for the requirements of a lean mid-market industrial business, with unclear roles, siloed functions, and limited operational accountability. Beyond the financial and structural challenges, the business was also facing a strategic and commercial crisis, with insufficient sales effectiveness and a lack of clear strategic direction to restore growth and competitiveness. While the business retained strong industrial capabilities and attractive market positions, immediate stabilization and fundamental transformation were required.
Immediate stabilization of liquidity and business operations through rigorous cash management, working capital optimization, and restructuring measures
Execution of a broad operational transformation covering cost reduction, footprint reorganization, productivity improvement, operational excellence initiatives, and production strategy
Strategic repositioning of the business through product portfolio realignment, increasing the share of higher-margin specialty products, strengthening R&D capabilities, and investing into two new foil machines to secure future competitiveness
Active management of financing and M&A processes to adapt the transformation path to evolving market conditions and create strategic optionality
Transparent stakeholder management and disciplined performance governance to maintain alignment across shareholders, lenders, and employees throughout the transformation journey
Equity value increase
(engagement exit vs. entry)
> 2.0x entry EBITDA
Trade sale of both American and European business
> € 25 m
> 40%
Bickel & Company
We take on mandates only if we can deliver on what you need.
Speak with an Executive Partner.
We use essential cookies to run this site. With your consent we also measure which pages get read, so we can keep improving them. You can change your mind at any time — see our privacy policy.